drugset / Trial / NCT01450683
Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy
NaSingle-groupOpen-labelTreatment
Summary
This study evaluates if itraconazole causes a reduction in the serum levels of prostate-specific antigen (PSA) in male subjects with castration-resistant prostate cancer (CRPC).
Timeline
- Start
- 2010-09
- Primary completion
- 2011-04
- Completion
- 2011-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Itraconazole | Small molecule | 600 mg | Oral |